TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02148198

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A combination of sweetener + aroma, which was equal to the combination used in the intervention period was given as placebo comparator.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A combination of sweetener + aroma, which was equal to the combination used in the intervention period was given as placebo comparator.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A combination of sweetener + aroma, which was equal to the combination used in the intervention period was given as placebo comparator.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A combination of sweetener + aroma, which was equal to the combination used in the intervention period was given as placebo comparator.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A combination of sweetener + aroma, which was equal to the combination used in the intervention period was given as placebo comparator.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A combination of sweetener + aroma, which was equal to the combination used in the intervention period was given as placebo comparator.
Study: NCT01640223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom7
Description: patients will wear 2 Dexcom sensors 3 days before hospitalization.
Study: NCT03943940

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM-MNC and UC-MSC
Description: Autologous bone marrow mononuclear cells (BM-MNCs) and allogeneic umbilical cord tissue-derived mesenchymal stem cells (UC-MSCs) under sterile conditions to treat this disease.~UC-MSC: 1-2 x 10\^6 cells/kg
Study: NCT02289911

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Didactic training in the FAST
Description: Participants in the classroom group (class) listened to traditional lectures, while the web group (web) watched narrated lectures online. All participants completed a pre- and post-test, and a second post-test eight weeks later. Both groups underwent hands-on training after the first post-test.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Didactic training in the FAST
Description: Participants in the classroom group (class) listened to traditional lectures, while the web group (web) watched narrated lectures online. All participants completed a pre- and post-test, and a second post-test eight weeks later. Both groups underwent hands-on training after the first post-test.
Study: NCT02870517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxing Music
Description: Relaxing music, will be played through noise-cancelling headphones during induction of anesthesia. All of the songs used in this study will have \<60 BPM, be instrumental rather than lyrical, and utilize predictable chord progressions. Music will be divided into several themed playlists which will be focused on the type of instruments involved including guitar, steel drum, and piano. The patient will listen to the music through noise-cancelling headphones beginning fifteen minutes prior to induction and ending one minute after intubation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Music
Description: The patient will wear noise-cancelling headphones beginning fifteen minutes prior to induction and ending one minute after intubation.
Study: NCT02032758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Single oral dose of 10 mg propranolol

Intervention type: DEVICE
Group type: OTHER
Intervention: Opal Device
Description: The Opal Device (APDM, Inc.) will be used to measure wrist movement.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Opal Device
Description: The Opal Device (APDM, Inc.) will be used to measure wrist movement.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Science and Motion PuttLab (SAM)
Description: The SAM will be used to study putter stroke movement and ball movement.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Science and Motion PuttLab (SAM)
Description: The SAM will be used to study putter stroke movement and ball movement.

Intervention type: DEVICE
Group type: OTHER
Intervention: Surface Electromyography EMG
Description: The surface EMG will be used to evaluate co-contraction of the wrist flexor/extensor muscle groups and the wrist pronator/supinator muscle groups.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surface Electromyography EMG
Description: The surface EMG will be used to evaluate co-contraction of the wrist flexor/extensor muscle groups and the wrist pronator/supinator muscle groups.
Study: NCT02919202

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colgate Fluoride Varnish Suspension. 2.26% Sodium Fluoride.
Description: Topical application to exposed dentine on one occasion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Self-etching Dentine Bonding Agent
Description: Topical application to exposed dentine on one occasion followed by light-curing procedure.
Study: NCT01241188

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-Tb
Description: The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2 TU Tuberculin PPD RT 23 SSI
Description: The 2 TU Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
Study: NCT02931513

Intervention type: OTHER
Intervention: Blood samples

Intervention type: DEVICE
Intervention: Fibroscan

Intervention type: OTHER
Intervention: Questionnaires

Intervention type: BIOLOGICAL
Intervention: Liver biopsy
Description: Liver biopsy will only be obtained if obtained as part of the diagnosis (will not be obtained for study purpose only)
Study: NCT02074670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill gait training
Description: Five days a week, 40 sessions of Kinesiotherapy (passive and active mobilizations, muscle lengthening), Body Weight Supported Treadmill Training, bicycle, manual therapy (with and without assistance of a mechanical device) and daily life activities training.
Study: NCT02214888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRB 796 BS, low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRB 796 BS, high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04157153

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of a Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold
Description: Subjects with symptomatic coronary artery disease who qualify for percutaneous coronary intervention (PCI) will be treated with a sirolimus eluting resorbable coronary Magnesium scaffold
Study: NCT04102800

Intervention type: DRUG
Group type: OTHER
Intervention: Benralizumab
Description: subcutaneous injection
Study: NCT04060888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab (approximately 6 mg/kg)
Description: Participants will receive ustekinumab approximately 6 milligram per kilogram via IV route based on body weight-range.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 milligram (mg)
Description: Participants will receive 90 mg ustekinumab via SC route.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matching to ustekinumab IV or SC.
Study: NCT01869036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: caudal anesthesia
Description: Standard caudal anesthesia (Marcaine 2mg/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: caudal anesthesia supplemented with morphine
Description: Caudal anesthesia supplemented with Morphine (10 µg/kg in children less than 10 kg and 20 µg/kg in children more than 10 kg)
Study: NCT02360670

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: additional multimodal imaging
Study: NCT05749991

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dryshield
Description: DryShield combines the tasks of high-suction evacuator, saliva ejector, bite block, tongue shield, and oral pathway protector in one easy-to-use device.~The DryShield solution® is a patented autoclavable isolation system (MA, USA)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cotton roll isolation
Description: Cotton Roll Isolation requires placing cotton rolls along the buccal mucosa, especially over the parotid glands ducts for maxillary teeth. For the mandibular teeth, the cotton rolls are placed in the buccal vestibule and the floor of the mouth (between the lower buccal mucosa and underneath and/or between the tongue). With this technique, a high-speed evacuation of saliva and water is used.
Study: NCT00840268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxypropyl Guar Galactomannan (HPGG) 0.25% ophthalmic gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxypropyl Guar Galactomannan Vehicle
Description: Inactive ingredients used as a placebo comparator
Study: NCT04332536

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise with and without Codeine
Description: This study will use our novel CPX test that incorporates instantaneous assessment of maximal isokinetic cycling power at V̇O2peak to elucidate the mechanisms that limit V̇O2peak in CHF, and compare these responses with age-matched controls.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise with and without Codeine
Description: This study will use our novel CPX test that incorporates instantaneous assessment of maximal isokinetic cycling power at V̇O2peak to elucidate the mechanisms that limit V̇O2peak in CHF, and compare these responses with age-matched controls.
Study: NCT00946608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg Tablets Under Fasting Conditions (Sandoz, Inc.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg Tablets Under Fed Conditions (Sandoz, Inc.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Claritin (Loratadine) 10 mg Tablets Under Fed Conditions (Schering)
Study: NCT01640223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom7
Description: patients will wear 2 Dexcom sensor one day before hospitalization
Study: NCT01777100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Sufentanil 0.5 mcg.kg-1 at anesthesia induction (single dose)
Study: NCT03428360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category
Description: The subjects in this study administered DBF themselves or with the help of a caregiver, (trained by the study site staff in study drug administration and documentation) in the same setting as they typically used the diazepam rectal gel or other rescue medication, without the presence of study staff.
Study: NCT01414855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obinutuzumab
Description: 1000 mg intravenously on Day 1 of each 21-day cycle, 8 cycles; during Cycle 1 administration also on Days 8 and 15.
Study: NCT01800487

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: silymarin
Description: 140 mg three times a day for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (silymarin) 1 tab three times a day for 4 weeks
Study: NCT01616472

Intervention type: DRUG
Intervention: Cumulative corticosteroid exposure
Description: Cumulative steroid exposure will be modeled as cumulative dose (prednisone equivalent mg), cumulative days of exposure at any dose, cumulative days of exposure to doses ≥7.5mg and cumulative days of exposure to doses ≥20mg.

Intervention type: DRUG
Intervention: Cumulative corticosteroid exposure
Description: Cumulative steroid exposure will be modeled as cumulative dose (prednisone equivalent mg), cumulative days of exposure at any dose, cumulative days of exposure to doses ≥7.5mg and cumulative days of exposure to doses ≥20mg.

Intervention type: DRUG
Intervention: Cumulative corticosteroid exposure
Description: Cumulative steroid exposure will be modeled as cumulative dose (prednisone equivalent mg), cumulative days of exposure at any dose, cumulative days of exposure to doses ≥7.5mg and cumulative days of exposure to doses ≥20mg.

Intervention type: DRUG
Intervention: Cumulative corticosteroid exposure
Description: Cumulative steroid exposure will be modeled as cumulative dose (prednisone equivalent mg), cumulative days of exposure at any dose, cumulative days of exposure to doses ≥7.5mg and cumulative days of exposure to doses ≥20mg.

Intervention type: DRUG
Intervention: Cumulative corticosteroid exposure
Description: Cumulative steroid exposure will be modeled as cumulative dose (prednisone equivalent mg), cumulative days of exposure at any dose, cumulative days of exposure to doses ≥7.5mg and cumulative days of exposure to doses ≥20mg.

Intervention type: DRUG
Intervention: Cumulative corticosteroid exposure
Description: Cumulative steroid exposure will be modeled as cumulative dose (prednisone equivalent mg), cumulative days of exposure at any dose, cumulative days of exposure to doses ≥7.5mg and cumulative days of exposure to doses ≥20mg.

Intervention type: DRUG
Intervention: Cumulative corticosteroid exposure
Description: Cumulative steroid exposure will be modeled as cumulative dose (prednisone equivalent mg), cumulative days of exposure at any dose, cumulative days of exposure to doses ≥7.5mg and cumulative days of exposure to doses ≥20mg.

Intervention type: DRUG
Intervention: Cumulative corticosteroid exposure
Description: Cumulative steroid exposure will be modeled as cumulative dose (prednisone equivalent mg), cumulative days of exposure at any dose, cumulative days of exposure to doses ≥7.5mg and cumulative days of exposure to doses ≥20mg.

Intervention type: DRUG
Intervention: Cumulative corticosteroid exposure
Description: Cumulative steroid exposure will be modeled as cumulative dose (prednisone equivalent mg), cumulative days of exposure at any dose, cumulative days of exposure to doses ≥7.5mg and cumulative days of exposure to doses ≥20mg.

Intervention type: DRUG
Intervention: Cumulative corticosteroid exposure
Description: Cumulative steroid exposure will be modeled as cumulative dose (prednisone equivalent mg), cumulative days of exposure at any dose, cumulative days of exposure to doses ≥7.5mg and cumulative days of exposure to doses ≥20mg.
Study: NCT02697305

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IV BCAA
Description: in total dose of 0,4 g/kg in a 2 h intravenous infusion

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ORAL BCAA
Description: single dose of 0.4g/kg administered over 30s washed down with 500mL of tap water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ORAL Placebo
Description: single dose of 0.4 g/kg administered over 30 s washed down with 500mL of tap water
Study: NCT00918203

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: 15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, administered intravenously (IV) at 25 milligram/minute (mg/min), with a minimum infusion time of 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200 mg/m2 is then administered IV over 3 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 200 mg/m2 is then administered IV over 3 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.
Study: NCT02644369

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
Study: NCT05119543

Intervention type: OTHER
Intervention: outdoor time
Description: This cohort study aimed to assess the change of refractive status in Chinese school children under different outdoor time
Study: NCT00781118

Intervention type: DEVICE
Group type: OTHER
Intervention: Guardian System
Description: There is no intervention in this study. The device is a diagnostic only.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian System
Description: There is no intervention in this study. The device is a diagnostic only.
Study: NCT00354237

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional antidiabetic treatment
Description: No intensive treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment
Description: Intensive insulin treatment
Study: NCT03919110

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of biological samples
Description: Investigators are building a collection of biological samples to perform biological assays and multiple analyses so-called omics: genomics (on the entire genome), proteomics (on all proteins) etc...This will make it possible to identify the genetic mutations or biological markers present or absent in these diseases, making it possible to confirm a diagnosis or to eliminate differential diagnoses.

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of biological samples
Description: Investigators are building a collection of biological samples to perform biological assays and multiple analyses so-called omics: genomics (on the entire genome), proteomics (on all proteins) etc...This will make it possible to identify the genetic mutations or biological markers present or absent in these diseases, making it possible to confirm a diagnosis or to eliminate differential diagnoses.

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of biological samples
Description: Investigators are building a collection of biological samples to perform biological assays and multiple analyses so-called omics: genomics (on the entire genome), proteomics (on all proteins) etc...This will make it possible to identify the genetic mutations or biological markers present or absent in these diseases, making it possible to confirm a diagnosis or to eliminate differential diagnoses.

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of biological samples
Description: Investigators are building a collection of biological samples to perform biological assays and multiple analyses so-called omics: genomics (on the entire genome), proteomics (on all proteins) etc...This will make it possible to identify the genetic mutations or biological markers present or absent in these diseases, making it possible to confirm a diagnosis or to eliminate differential diagnoses.
Study: NCT03492866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin Sulfate
Description: Topical treatment of 1 side of the scalp twice daily during 6 months
Study: NCT03657316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutrition education
Description: The content of the three days workshop:Healthy diet, Diet-related health risks and diseases, Physical activity The sustained multi-component program will be based on The three days nutritional and physical education workshop Enhanced physical education Involvement of the morning broadcast in provision of messages for students about nutrition and physical activity Brochure including key messages about diet and physical activity will be designed and sent to parents of the intervention classes of students A monthly telephone call or a text message will be sent to the parents to remind them about the commitment to the dietary health practices.~Message to school administration to prevent selling of soft drinks and to sell healthy food A monthly session for three months will be held to remind the students with the messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutrition education
Description: The content of the three days workshop:Healthy diet, Diet-related health risks and diseases, Physical activity The sustained multi-component program will be based on The three days nutritional and physical education workshop Enhanced physical education Involvement of the morning broadcast in provision of messages for students about nutrition and physical activity Brochure including key messages about diet and physical activity will be designed and sent to parents of the intervention classes of students A monthly telephone call or a text message will be sent to the parents to remind them about the commitment to the dietary health practices.~Message to school administration to prevent selling of soft drinks and to sell healthy food A monthly session for three months will be held to remind the students with the messages
Study: NCT01155206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucagon
Description: glucagon 3ng/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucagon
Description: glucagon 3ng/kg/min
Study: NCT00258830

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone®: Influenza Virus Vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone®: Influenza Virus Vaccine
Description: 0.5 mL, Intramuscular
Study: NCT03615352

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ovarian cystectomy
Description: laparoscopic ovarian cystectomy in endometrioma

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ovarian cyst aspiration and coagulation
Description: laparoscopic ovarian cyst aspiration and coagulation in endometrioma
Study: NCT03558269

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autlogous UCB infusion
Description: Infants delivered with hypoplastic left heart syndrome and transposition of great arteries undergoing surgery in the 1st 2 weeks of life will be treated with autologous UCB after the surgery. Each group will be followed by MRI before (1-3 days) and after the surgery between at 10 POD. Developmental follow up will be done at 1, 6 and 12 months. Another brain MRI will be done at 6 months of age.
Study: NCT03943940

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Standard medicine